Based on the key indicators related to Citius Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Citius Pharmaceuticals is not in a good financial situation at this time. It has a very high probability of going through financial hardship in December. At this time, Citius Pharmaceuticals' Non Current Liabilities Total is relatively stable compared to the past year. As of 11/25/2024, Total Liabilities is likely to grow to about 14.7 M, while Other Current Liabilities is likely to drop slightly above 1.7 M. Key indicators impacting Citius Pharmaceuticals' financial strength include:
Investors should never underestimate Citius Pharmaceuticals' ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Citius Pharmaceuticals' cash flow, debt, and profitability to make informed and accurate decisions about investing in Citius Pharmaceuticals.
Net Income
(27.82 Million)
Citius
Select Account or Indicator
Market Cap
Enterprise Value
Ptb Ratio
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Average Payables
Capex To Depreciation
Pb Ratio
Free Cash Flow Per Share
Roic
Net Income Per Share
Payables Turnover
Cash Per Share
Pocfratio
Interest Coverage
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Intangibles To Total Assets
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Graham Number
Shareholders Equity Per Share
Debt To Equity
Graham Net Net
Interest Debt Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Short Term Coverage Ratios
Price Earnings Ratio
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Ebt Per Ebit
Effective Tax Rate
Company Equity Multiplier
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Net Income Per E B T
Cash Ratio
Cash Flow Coverage Ratios
Price To Book Ratio
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Return On Assets
Price Fair Value
Return On Equity
Change In Cash
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Other Cashflows From Financing Activities
Other Non Cash Items
Capital Expenditures
Total Cash From Operating Activities
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Net Borrowings
Cash And Cash Equivalents Changes
Change To Netincome
Change To Liabilities
Sale Purchase Of Stock
Investments
Total Cashflows From Investing Activities
Depreciation
Change To Account Receivables
Change To Operating Activities
Other Cashflows From Investing Activities
Change Receivables
Stock Based Compensation
Cash Flows Other Operating
Issuance Of Capital Stock
Total Assets
Short Long Term Debt Total
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Net Debt
Retained Earnings
Accounts Payable
Cash
Cash And Short Term Investments
Common Stock Total Equity
Common Stock Shares Outstanding
Liabilities And Stockholders Equity
Non Current Liabilities Total
Total Liab
Total Current Assets
Short Term Debt
Common Stock
Net Tangible Assets
Retained Earnings Total Equity
Capital Surpluse
Other Stockholder Equity
Other Liab
Non Current Assets Total
Other Assets
Good Will
Other Current Assets
Deferred Long Term Liab
Short Long Term Debt
Intangible Assets
Property Plant Equipment
Non Currrent Assets Other
Property Plant And Equipment Net
Property Plant And Equipment Gross
Net Invested Capital
Net Working Capital
Capital Stock
Capital Lease Obligations
Non Current Liabilities Other
Depreciation And Amortization
Interest Expense
Selling General Administrative
Other Operating Expenses
Operating Income
Ebit
Ebitda
Total Operating Expenses
Income Before Tax
Total Other Income Expense Net
Net Income From Continuing Ops
Net Income Applicable To Common Shares
Gross Profit
Research Development
Cost Of Revenue
Income Tax Expense
Interest Income
Non Operating Income Net Other
Net Interest Income
Reconciled Depreciation
Probability Of Bankruptcy
Understanding current and past Citius Pharmaceuticals Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Citius Pharmaceuticals' financial statements are interrelated, with each one affecting the others. For example, an increase in Citius Pharmaceuticals' assets may result in an increase in income on the income statement.
Citius Pharmaceuticals competes with X4 Pharmaceuticals, Hookipa Pharma, Mereo BioPharma, Acumen Pharmaceuticals, and Fortress Biotech. Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey. Citius Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 15 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Citius Pharmaceuticals Key Income Statement Accounts
The reason investors look at the income statement is to determine what Citius Pharmaceuticals' earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
Comparative valuation techniques use various fundamental indicators to help in determining Citius Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Citius Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Citius Pharmaceuticals competition to find correlations between indicators driving Citius Pharmaceuticals's intrinsic value. More Info.
Citius Pharmaceuticals is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Citius Pharmaceuticals' Return On Equity is relatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Citius Pharmaceuticals by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Citius Pharmaceuticals Systematic Risk
Citius Pharmaceuticals' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Citius Pharmaceuticals volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twelve with a total number of output elements of fourty-nine. The Beta measures systematic risk based on how returns on Citius Pharmaceuticals correlated with the market. If Beta is less than 0 Citius Pharmaceuticals generally moves in the opposite direction as compared to the market. If Citius Pharmaceuticals Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Citius Pharmaceuticals is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Citius Pharmaceuticals is generally in the same direction as the market. If Beta > 1 Citius Pharmaceuticals moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Citius Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Citius Pharmaceuticals' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Citius Pharmaceuticals growth as a starting point in their analysis.
Citius Pharmaceuticals November 25, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Citius Pharmaceuticals help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Citius Pharmaceuticals. We use our internally-developed statistical techniques to arrive at the intrinsic value of Citius Pharmaceuticals based on widely used predictive technical indicators. In general, we focus on analyzing Citius Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Citius Pharmaceuticals's daily price indicators and compare them against related drivers.
When running Citius Pharmaceuticals' price analysis, check to measure Citius Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Citius Pharmaceuticals is operating at the current time. Most of Citius Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Citius Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Citius Pharmaceuticals' price. Additionally, you may evaluate how the addition of Citius Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.